A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer S. Novello1,, B. Besse2,*, E. Felip3, F. Barlesi4, J. Mazieres5, G. Zalcman6, J. von Pawel7, M. Reck8, F. Cappuzzo9, D. Ferry10,, E. Carcereny11, A. Santoro12, I. Garcia-Ribas13, G. Scagliotti1 & J.-C. Soria2 Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy; Thoracic Cancer Unit, Department of Medicine, Gustave-Roussy, Villejuif, France; Department of Medical Oncology, Vall d’Hebron Institute of Oncology, Barcelona, Spain; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Department of Pneumology and Allergies, CHU Toulouse Hôpital Larrey, Toulouse; Department of Pneumology, CHU Côte de Nacre, Caen, France; Department of Oncology, Asklepios Fachkliniken München-Gauting, Gauting; Thoracic Oncology, LungenClinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Department of Medical Oncology, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy; Department of Oncology, New Cross Hospital, Wolverhampton, UK; Department of Medical Oncology, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Department of Medical Oncology, Humanitas Cancer Center IRCCS, Milan, Italy; Oncology Division, Sanofi Aventis, Barcelona, Spain